GlobeNewswire

For those striving to reach the pinnacle of success, the Warwick Business School offers an MBA that helps professional dreams come true

Dela

LONDON, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Let's face it, undergraduate degrees are commonplace these days. They provide a great foundation, but are by no means the differentiating factor they used to be. Fortunately, those seeking to stand out from the crowd need look no further than the Executive MBA at Warwick Business School (WBS) - one of the UK's best-rated universities.

In an exclusive interview with European CEO magazine, WBS alumna Jann Gardner, now Director of Planning and Strategic Partnerships at NHS Fife, revealed: "Most people believe the WBS MBA is a symbol of an individual's calibre."

The course involves core modules ranging from financial management to organisational behaviour, as well as an array of electives, such as entrepreneurship and big data transformation.

"In addition, WBS has partnered with a range of high-quality business schools around the world to offer specific modules," Gardner told European CEO. "I personally had the pleasure of studying at WBS, the Shard and the Erasmus University in Rotterdam. I also plan to attend further modules at ESADE, Barcelona."

There are many reasons high-flying professionals choose to undertake an Executive MBA at WBS in spite of their hectic schedules, from bettering their chances of promotion to enhancing their future earning potential and extending their skillsets.

With an MBA from WBS, individuals are well placed to reach the pinnacle of success in their respective fields. Like many alumni before them, they can become industry-leading entrepreneurs, CEOs of global corporations, financial heavyweights and government leaders.

To find out more about the MBA offered by Warwick Business School, check out an  exclusive interview  with alumna Jann Gardner in the latest edition of European CEO, available in print, on tablet and online now.

www.europeanceo.com

World News Media is a leading publisher of quality financial and business magazines, which enjoys a global distribution network that includes subscriber lists of prominent decision-makers around the world.

CONTACT INFORMATION

World News Media
Elizabeth Matsangou
Editorial Department
+44 (0)20 7553 4162
elizabeth.matsangou@wnmedia.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: European CEO via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics appoints a new Chief Medical Officer25.3.2019 11:00:00 CETPressmeddelande

STOCKHOLM, March 25, 2019. Karolinska Development's portfolio company Aprea Therapeutics announces today that Dr. Eyal C. Attar has been appointed to a position as Senior Vice President and Chief Medical Officer (CMO). Dr. Attar joins Aprea from Agios Pharmaceuticals, where he was Senior Medical Director and IDH Hematology Medical Lead. Having served at Agios since 2014, Dr. Attar played a leadership role in the clinical development and approval of Idhifa and Tibsovo for patients with relapsed/refractory Acute Myeloid Leukemia (AML). Prior to Agios, he served on the clinical staff at the Massachusetts General Hospital Cancer Center, where Dr. Attar was a member of the Center for Leukemia and Assistant Professor of Medicine at Harvard Medical School. "Dr. Attar's deep medical and biotech industry experiences will strengthen our clinical development efforts as we continue to advance our first-in-class p53 reactivating agents in late-stage clinical studies", states Christian S. Schade, Pr

Karolinska Development's portfolio company Aprea Therapeutics appoints a new Chief Medical Officer25.3.2019 11:00:00 CETPressmeddelande

STOCKHOLM, March 25, 2019. Karolinska Development's portfolio company Aprea Therapeutics announces today that Dr. Eyal C. Attar has been appointed to a position as Senior Vice President and Chief Medical Officer (CMO). Dr. Attar joins Aprea from Agios Pharmaceuticals, where he was Senior Medical Director and IDH Hematology Medical Lead. Having served at Agios since 2014, Dr. Attar played a leadership role in the clinical development and approval of Idhifa and Tibsovo for patients with relapsed/refractory Acute Myeloid Leukemia (AML). Prior to Agios, he served on the clinical staff at the Massachusetts General Hospital Cancer Center, where Dr. Attar was a member of the Center for Leukemia and Assistant Professor of Medicine at Harvard Medical School. "Dr. Attar's deep medical and biotech industry experiences will strengthen our clinical development efforts as we continue to advance our first-in-class p53 reactivating agents in late-stage clinical studies", states Christian S. Schade, Pr

Immunicum AB (publ) meddelar kommande konferenser i mars och april22.3.2019 08:00:00 CETPressmeddelande

Pressmeddelande 22 mars 2019 Immunicum AB (publ) meddelar kommande konferenser i mars och april Immunicum AB (publ; IMMU.ST) meddelar idag att medlemmar av ledningsgruppen kommer att delta och presentera vid kommande konferenser i mars och april. BIO-Europe Spring Datum: 25-27 mars 2019 Plats: Messe Wien Exhibition and Congress Center, Wien, Österrike Deltagare: Sijme Zeilemaker China Focus @ Europe Vienna Datum: 27 mars 2019 Paneltid/Sessionstid: 16.10 - 17.00, Panel 4: Partnering Opportunities with Chinese Pharma Plats: Hilton Vienna Danube Waterfront, Wien, Österrike Deltagare: Carlos de Sousa Swedish American Life Science Summit 2019 Datum: 9-10 april 2019 Presentationsdatum: Onsdagen 10 april 2019 Plats: House of Sweden, 2900 K St. NW, Washington D.C. 20008 Deltagare: Carlos de Sousa För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 8 732 8400 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@i

Immunicum AB (publ) Announces Upcoming Conferences in March and April22.3.2019 08:00:00 CETPressmeddelande

Press Release 22 March 2019 Immunicum AB (publ) Announces Upcoming Conferences in March and April Immunicum AB (publ; IMMU.ST) announced today that members of the management team will attend and present at upcoming conferences in March and April. BIO-Europe Spring Date: March 25-27, 2019 Venue: Messe Wien Exhibition and Congress Center, Vienna, Austria Participant: Sijme Zeilemaker China Focus @ Europe Vienna Date: March 27, 2019 Panel Time/Session: 16.10 - 17.00, Panel 4: Partnering Opportunities with Chinese Pharma Venue: Hilton Vienna Danube Waterfront, Vienna, Austria Participant: Carlos de Sousa Swedish American Life Science Summit 2019 Date: April 9-10, 2019 Presentation Date: Wednesday, April 10, 2019 Venue: House of Sweden, 2900 K St. NW, Washington D.C. 20008 Participant: Carlos de Sousa For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 8 732 8400 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir

Karolinska Development's portfolio company Promimic announces partnership with Onkos Surgical15.3.2019 08:45:00 CETPressmeddelande

STOCKHOLM, March 15, 2019. Karolinska Development's portfolio company Promimic announces a new partnership with the U.S company Onkos Surgical® to commercialize Promimic's proprietary Hydroxyapatite (HA) Surface Technologies in Limb Salvage Surgery. Promimic develops and markets products within nano-materials for innovative surface treatments and has developed the HA nano Surface that is clinically proven to speed up and improve the anchoring of implants in bone. The innovative technology is already licensed to several dental implant companies. The partnership with Onkos Surgical®, a U.S company addressing the clinical challenges associated with tumor surgery, represents an important step into the orthopaedic space. The partnership will focus on combining Promimic's HA nano Surface Technology with Onkos Surgical®'s ELEOS Limb Salvage Portfolio. Implant failure due to aseptic loosening remains one of the key challenges associated with limb salvage surgery. With HA nano Surface, Onkos Su

Karolinska Development's portfolio company Promimic announces partnership with Onkos Surgical15.3.2019 08:45:00 CETPressmeddelande

STOCKHOLM, March 15, 2019. Karolinska Development's portfolio company Promimic announces a new partnership with the U.S company Onkos Surgical® to commercialize Promimic's proprietary Hydroxyapatite (HA) Surface Technologies in Limb Salvage Surgery. Promimic develops and markets products within nano-materials for innovative surface treatments and has developed the HA nano Surface that is clinically proven to speed up and improve the anchoring of implants in bone. The innovative technology is already licensed to several dental implant companies. The partnership with Onkos Surgical®, a U.S company addressing the clinical challenges associated with tumor surgery, represents an important step into the orthopaedic space. The partnership will focus on combining Promimic's HA nano Surface Technology with Onkos Surgical®'s ELEOS Limb Salvage Portfolio. Implant failure due to aseptic loosening remains one of the key challenges associated with limb salvage surgery. With HA nano Surface, Onkos Su

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum